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        Defective myeloid cell diff  erentiation is one of 
the major factors underlying the immune non-
responsiveness of both solid tumors and hema-
tological malignancies (  1  ). Consequences of 
defective myeloid cell diff  erentiation include 
decreased production of mature, functionally 
competent DCs and accumulation of myeloid-
derived suppressor cells (MDSCs) (  2  –  4  ). MD-
SCs are a mixed group of myeloid cells including 
immature granulocytes, macrophages, DCs, and 
myeloid progenitors. In mice, MDSCs with 
the phenotype of Gr-1  +  CD11b  +   cells were de-
tected in practically all tested tumor models. 
Signifi  cant accumulation of these cells was found 
in patients with various types of cancer (  5  –  9  ). 
Numerous studies have demonstrated a critical 
role of MDSCs in the suppression of T cell re-
sponses and induction of T cell tolerance in 
cancer (  10  –  13  ). MDSCs may account in large 
part for the limited eff  ectiveness of cancer vac-
cines and other therapies such as anti  –  vascular 
endothelial growth factor (VEGF) treatment 
(  8, 14, 15  ). Recent studies have also demon-
strated an important function of these cells in 
infection, infl  ammation, and prevention of graft 
rejection (  16  –  20  ). 
  Despite the wealth of information regarding 
the functional importance of MDSCs, the mech-
anism responsible for their accumulation re-
mains unknown. Various tumor-derived factors 
(VEGF, IL-6, IL-10, M-CSF, and GM-CSF) 
can inhibit DC diff  erentiation from hemato-
poietic progenitor cells (HPCs) in vitro and 
in vivo (  1  ). In search of specifi  c genes responsible 
for abnormal myeloid cell diff  erentiation in 
cancer, we evaluated the eff  ect of VEGF on 
HPC gene expression by diff  erential display 
analysis and consistently found up-regulation of 
the mouse   S100A9   gene. S100A9, also referred 
to as myeloid-related protein 14 (MRP14) or 
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  Accumulation of myeloid-derived suppressor cells (MDSCs) associated with inhibition of 
dendritic cell (DC) differentiation is one of the major immunological abnormalities in 
cancer and leads to suppression of antitumor immune responses. The molecular mechanism 
of this phenomenon remains unclear. We report here that STAT3-inducible up-regulation of 
the myeloid-related protein S100A9 enhances MDSC production in cancer. Mice lacking 
this protein mounted potent antitumor immune responses and rejected implanted tumors. 
This effect was reversed by administration of wild-type MDSCs from tumor-bearing mice to 
S100A9-null mice. Overexpression of S100A9 in cultured embryonic stem cells or trans-
genic mice inhibited the differentiation of DCs and macrophages and induced accumulation 
of MDSCs. This study demonstrates that tumor-induced up-regulation of S100A9 protein is 
critically important for accumulation of MDSCs and reveals a novel molecular mechanism 
of immunological abnormalities in cancer. 
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tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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calgranulin B, is a member of the large family of S100 pro-
teins. It is expressed together with its dimerization partner 
S100A8 (MRP8 or calgranulin A) in circulating neutrophils 
and monocytes, but not in resting tissue macrophages (  21  ). 
S100A9 protein contains two helix  –  loop  –  helix motifs (EF-
hand), which have high affi   nity for Ca  2+   (  22  ). Upon eleva-
tion of intracellular calcium, S100A8 and S100A9 translocate 
from the cytosol to the cytoskeleton and the plasma mem-
brane of myeloid cells (  23  ) and are released as a heterodimer 
to recruit leukocytes to sites of infl  ammation or tumors (  24  ). 
Until now, their role in myeloid cell diff  erentiation remained 
unknown. We report here that up-regulation of S100A9 in 
myeloid precursors in cancer inhibits DC and macrophage 
diff  erentiation and induces accumulation of MDSCs. This 
may represent a universal molecular mechanism of tumor-in-
duced abnormalities in myeloid cells in cancer, directly link-
ing infl  ammation and immune suppression. 
    RESULTS   
  S100A9 expression is associated with accumulation 
of MDSCs in cancer 
    S100A9   and   S100A8   mRNAs and proteins were readily de-
tectable in enriched bone marrow HPCs, but gradually de-
creased during culture with GM-CSF and IL-4 and were 
almost undetectable by day 7, when   >  70% of cells in culture 
were DCs (  Fig. 1 A   and Fig. S1, A and B, available at http://
www.jem.org/cgi/content/full/jem.20080132/DC1).   Thus, 
under physiological conditions, DC diff  erentiation was associ-
ated with marked down-regulation of S100A8 and S100A9. 
To evaluate the eff  ect of tumor-derived factors on S100A9 ex-
pression, HPCs were cultured for 7 d with GM-CSF and IL-4 
in CT-26 tumor cell  –  conditioned medium (TCM) or 3T3 
fi  broblast-conditioned medium (FCM). TCM prevented the 
down-regulation of   S100A9   mRNA expression during diff  er-
entiation in vitro (  Fig. 1 A  ). Previous studies have shown that 
in contrast to FCM, TCM inhibits the diff  erentiation of DCs 
from HPCs and induces the accumulation of Gr-1  +  CD11b  +   
MDSCs (  25  –  27  ). To verify the suppressive activity of these 
MDSCs, HPCs were cultured for 5 d with GM-CSF, IL-4, 
and TCM. Consistent with previous results, TCM substantially 
decreased the proportion of CD11c  +   DCs and increased the 
proportion of Gr-1  +  CD11b  +   MDSCs (Fig. S2). Gr-1  +  CD11b  +   
cells were then sorted and added to splenocytes from C57BL/6 
mice stimulated with anti-CD3/CD28 antibody or to OT-1 
splenocytes (CD8  +   T cells from these mice have a TCR that 
recognizes the OVA-derived peptide SIINFEKL) stimulated 
with control or specifi  c peptide. Gr-1  +  CD11b  +   cells generated 
in TCM signifi  cantly suppressed T cell responses (  Fig. 1 B  ). 
  We asked whether the observed up-regulation of S100A8 
and S100A9 by TCM was associated with MDSC accumula-
tion. Gr-1  +   cells isolated after a 5-d culture of HPCs with 
GM-CSF and IL-4 in TCM expressed substantially more 
S100A8 and S100A9 proteins than did Gr-1        cells (  Fig. 1 C  ). 
No diff  erences in the levels of S100A8 and S100A9 were 
found between Gr-1  +   cells isolated from populations cultured 
with FCM versus TCM. 
    Figure 1.         Expression of S100A9 and A8 in myeloid cells in tumor-
bearing mice.   (A) HPCs from bone marrow of naive mice were cultured 
with GM-CSF and IL-4 for 7 d in the presence of 25% (vol/vol) conditioned 
media from NIH 3T3 fi  broblasts (3T3) or CT26 colon cancer cells (CT26). 
RNA was extracted on days 0, 1, 3, and 7, and qRT-PCR was performed. 
The level of expression of   S100A9   was normalized to 18S rRNA. Two ex-
periments yielded the same results. (B) HPCs from naive C57BL/6 mice 
were cultured for 5 d with GM-CSF and IL-4 in complete medium alone 
(control) or conditioned media from EL-4 cells (TCM). Gr-1  +   cells were 
isolated at the end of 5-d culture and added at 1:4 ratio to splenocytes 
from OT-1 mice. The number of IFN-      –  producing cells in response to 
stimulation by the specifi  c or control peptides was evaluated in an 
ELISPOT assay and calculated per 2   ×   10  5   splenocytes. S.P. represents the 
number of spots in cells stimulated with control peptide subtracted from 
the number of spots in cells stimulated with specifi  c peptide. In parallel, 
Gr-1  +   cells were added at 1:4 ratio to splenocytes from naive C57BL/6 
mice and stimulated with 0.5   μ  g/ml anti-CD3 and 5   μ  g/ml anti-CD28 anti-
bodies. The number of IFN-     cells was evaluated in ELISPOT assay. Two 
experiments were performed. * represents the statistically signifi  cant (P   <   
0.05) differences between control and TCM groups. (C) HPCs from C57BL/6 
mice were cultured for 5 d with GM-CSF and IL-4 in the presence of con-
ditioned media (25% vol/vol) from NIH 3T3 fi  broblasts (NIH 3T3) or C3 
fi  brosarcoma cells (C3). Gr-1  +   or  Gr-1       cells were isolated using magnetic 
beads by two rounds of isolation. Proteins extracted from cells were sub-
jected to Western blotting using indicated antibodies. Two experiments 
with the same results were performed. (D) Expression of S100A8 and A9 
proteins in whole cell lysates of splenocytes from CT26 tumor-bearing 
mice. N, naive tumor-free mice. (E) Gr-1  +   and  Gr-1       cells were isolated 
from spleens of naive mice (control) or mice bearing 3-wk-old CT26 tumor 
(tumor) as described above. The levels of proteins were evaluated by West-
ern blotting. Two experiments with the same results were performed.     
  The correlation between MDSC accumulation and 
S100A8/A9 levels was investigated in CT26 colon carci-
noma-bearing mice. Consistent with previous observations 
(  28, 29  ), the proportion of MDSCs in the spleens of these JEM VOL. 205, September 29, 2008 
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diff  erences were found in the proportions of the populations 
of myeloid cells in spleens (Fig. S3 A, available at http://
www.jem.org/cgi/content/full/jem.20080132/DC1), blood, 
and bone marrow (not depicted) between wild-type and 
S100A9KO mice. Likewise, no signifi  cant diff  erences in the 
presence of the myeloid populations were observed after in 
vitro diff  erentiation of HPCs (Fig. S3 B). 
  To evaluate diff  erentiation of myeloid cells in the pres-
ence of tumor-derived factors, enriched HPCs isolated from 
S100A9KO mice and their wild-type littermates were cul-
tured with GM-CSF for 5 d in TCM. Consistent with previ-
ous observations (for review see [  1  ]), tumor-derived factors 
signifi  cantly reduced the diff  erentiation of DCs and macro-
phages and substantially increased the production of Gr-
1  +  CD11b  +   MDSCs in wild-type populations. In contrast, 
TCM did not appreciably inhibit the diff  erentiation of my-
eloid cells from S100A9KO mice (  Fig. 2 A  ).   Thus, loss of 
mice increased gradually during tumor growth, and by 3 wk 
after inoculation was more than fi  vefold higher than in the 
spleens of control mice (unpublished data). Amounts of 
S100A8 and S100A9 increased in spleens of tumor-bearing 
mice in parallel with MDSC accumulation (  Fig. 1 D  ). Similar 
to the in vitro experiments, S100A8/A9 proteins were de-
tected in the Gr-1  +  , but not the Gr-1        population, and no 
diff  erences in protein levels were noted between Gr-1  +   cells 
from naive and tumor-bearing mice (  Fig. 1 E  ). Thus, the in-
creased expression of S100A8 and S100A9 in spleens of tu-
mor-bearing mice and the TCM-inducible up-regulation of 
S100A8 and S100A9 in vitro are associated exclusively with 
the accumulation of MDSCs. 
  S100A9 is essential for MDSC accumulation in cancer 
  To determine whether MDSC accumulation requires S100A9, 
we examined S100A9-defi  cient (S100A9KO) mice (  32  ). No 
    Figure 2.         Lack of S100A9 affects generation of MDSCs under pathological conditions.   (A) Enriched HPCs were isolated from bone marrow of 
S100A9 KO mice (KO) and their wild-type littermates (WT). Cells were cultured with GM-CSF and IL-4 for 5 d in complete culture medium or in the pres-
ence of EL-4 TCM. The cell phenotypes were evaluated by fl  ow cytometry. Mean   ±   SD of the proportions of indicated cell populations from three mice are 
shown. (B) EL-4 cells (3   ×   10  5  ) were injected s.c. into wild-type (WT) or S100A9 knockout (KO) mice and tumor size was measured. Anti-CD8 antibody 
(200   μ  g) was injected i.p. into KO mice 3 and 1 d before injection of tumor cells. The S100A9KO group included 12 mice, WT group 15 mice, and KO mice 
treated with anti-CD8 antibody 5 mice. Tumor size for each mouse is shown. (C) Phenotypes of splenocytes from wild-type (S100A9  +/+  ) and knockout 
(S100A9     /    ) mice 15 d after EL-4 cell injection were evaluated using multicolor fl  ow cytometry. * represents statistically signifi  cant differences between 
the groups (P   <   0.05). (D) Wild-type and S100A9 knockout mice were injected s.c. with 200   μ  l of CFA. The presence of Gr-1  + CD11b +   cells was monitored 
in peripheral blood. Each group included 4 mice. Mean   ±   SD are shown. (E) Gr-1  + CD11b +   cells in spleens of wild-type and S100A9 knockout mice 
on day 12 after CFA injection. Four mice per genotype were analyzed. * represents statistically signifi  cant differences between the groups (P   <   0.05). 
(F)   S100A9    /      mice were injected s.c. with 2   ×   10  5   EL-4 tumor cells and then split into 2 groups of 5 mice. One group was left untreated (no transfer) and 
the other group was treated i.v. with 3   ×   10  6   Gr-1 + CD11b +   cells isolated from tumor-bearing wild-type mice (MDSC) on days 1, 3, 5, and 7 after tumor 
inoculation. Tumor size for each mouse is shown.     2238 S100A9 AND MYELOID CELL DIFFERENTIATION IN CANCER   | Cheng et al. 
CFA induced a more than fi  vefold increase in the proportion 
of circulating MDSCs in wild-type mice, which peaked on 
days 6  –  9 after injection and returned to control level by day 13. 
In contrast, the number of circulating MDSCs did not in-
crease in S100A9KO mice at any time point (  Fig. 2 D  ). A 
similar pattern was observed in spleens on day 13 after CFA 
injection (  Fig. 2 E  ). Thus, the absence of S100A9 protein 
prevents accumulation of MDSCs in response to CFA, as 
well as to tumor challenge. 
  To address the potential contribution of MDSC accumu-
lation to tumor rejection, we performed adoptive transfers of 
MDSCs. S100A9KO mice were injected with EL-4 lym-
phoma cells, and then split into two groups of fi  ve mice each. 
One group was untreated and the other group was injected 
with MDSCs isolated from EL-4 tumor-bearing wild-type 
mice. 4 out of 5 untreated S100A9KO mice rejected their 
tumors by day 17, whereas all 5 S100A9KO mice injected 
with MDSCs developed rapidly growing tumors (  Fig. 2 F  ). 
Collectively, these results suggest that the absence of MDSC 
accumulation in S100A9 KO mice is responsible for their 
ability to reject tumors. 
  S100A9 overexpression impairs differentiation of DCs 
and induces accumulation of MDSCs 
  We asked whether overexpression of S100A9 and A8 could 
directly regulate the diff  erentiation of DCs and other myeloid 
cells. To address this question, we generated stable clones 
of R1 embryonic stem (ES) cells that overexpress S100A8, 
S100A9, or both (S100A8/9). R1 ES cells transfected with 
empty vector or another member of S100 family, S100A1, 
served as controls. Cells were subjected to in vitro diff  erenti-
ation of DCs, as previously described (  33  ). The expression of 
  S100A8   and   S100A9   was verifi  ed by qRT-PCR, as well as 
by Western blotting (  Figs. 3, A and B  ).   Endogenous   S100A8   
and   S100A9   genes were expressed in the control ES cells, but 
were shut down in embryoid bodies (EBs). The expression of 
these genes in transfected ES cells was continuously main-
tained during cell culture (Fig. S7, available at http://www
.jem.org/cgi/content/full/jem.20080132/DC1). 
  On day 35 after the start of the cultures, cells generated 
from EBs were collected to evaluate their phenotype by 
fl  ow cytometry. The total numbers of these cells were simi-
lar in all groups (unpublished data). More than 80% of cells 
generated from control- or   S100A1  -transfected ES cells had 
a phenotype of mature DCs (CD11c  +  IA  b+   or CD11c  +  B7-
2  +  ;   Fig. 3 C  ). In sharp contrast, ES cells transfected with 
  S100A9   or   S100A8/A9   displayed a dramatically reduced 
ability to generate DCs. Instead of DCs, these ES cells pro-
duced predominantly Gr-1  +   cells. The eff  ect of   S100A8   on 
DC diff   erentiation was similar, although much less pro-
nounced.   S100A8   did not increase the level of Gr-1  +  CD11b  +   
cells (  Fig. 3 C  ). Reduced DC generation from S100A8/
9-transfected ES cells was verifi  ed in a functional test us-
ing the allogeneic mixed leukocyte reaction, a hallmark of 
DC activity. Cells diff  erentiated from S100A8/9 ES cells 
had a much lower ability to stimulate the proliferation of 
S100A9 prevents the defective diff  erentiation of TCM-
treated myeloid cells. 
  To evaluate the eff  ect of S100A9 defi  ciency on tumor 
growth, control and S100A9KO mice were injected s.c. 
with 5   ×   10  5   EL-4 lymphoma cells. By days 8  –  10 after in-
oculation, tumor growth was evident in all mice (  Fig. 2 B  ). 
Tumors continued to grow aggressively in all 15 wild-type 
mice. In sharp contrast, tumors were rejected in 9 out of 
12 S100A9KO mice (P = 0.0002). Mean tumor size in the 
remaining three S100A9KO mice was signifi  cantly smaller 
than in the wild-type mice (238.7   ±   51.8 vs. 521.5   ±   199.3, 
P = 0.008). Similar results were obtained in the C3 sar-
coma tumor model (Fig. S4, available at http://www.jem
.org/cgi/content/full/jem.20080132/DC1). 
  To investigate whether immunological mechanisms were 
involved in tumor rejection, S100A9KO mice were injected 
i.p. with 200   μ  g of anti-CD8 antibody 3 d and 1 d before tu-
mor injection. This treatment reduced the level of CD8  +   T 
cells in peripheral blood by more than fi  vefold (unpublished 
data). None of the S100A9KO mice treated with anti-CD8 
antibody rejected their tumors. Tumor growth in these mice 
was similar to that in S100A9 wild-type mice (  Fig. 2 B  ). 
Splenocytes were obtained from S100A9KO and wild-type 
littermates 12  –  13 d after injection of EL-4 cells and restimu-
lated for 6 d with irradiated EL-4 tumor cells. T cells were 
collected and used as eff  ectors in cytotoxicity assays against 
either EL-4 cells, unrelated B16 melanoma cells, or perito-
neal macrophages obtained from naive C57BL/6 mice. T 
cells from S100A9KO mice showed substantially higher cy-
totoxicity against EL-4 cells than did T cells from wild-type 
mice. However, no diff  erences were found in cytotoxicity 
against macrophages or B16 cells (Fig. S5, available at http://
www.jem.org/cgi/content/full/jem.20080132/DC1). Tu-
mors removed from wild-type mice 12 d after tumor cell 
injection had clearly visible infi  ltration of S100A9  +   cells 
and Gr-1  +   cells, whereas these cells were absent from tumors 
from S100A9KO mice (Fig. S6, A and B). Tumors from 
S100A9 KO mice had visible infi  ltration of CD8  +   and CD4  +   
T cells, which was absent in tumor from S100A9 wild-type 
mice (Fig. S6, C and D) Tumors from S100A9 wild-type 
mice had viable cells and infi  ltrated adjacent adipose tissue. In 
contrast, tumors from S100A9KO mice had extensive necro-
sis and apoptosis at the periphery (Fig. S6 E). By day 15 after 
tumor cell injection, tumor-bearing wild-type mice expressed 
substantially more Gr-1  +  CD11b  +   MDSCs than did tumor-
free mice (11% in   Fig. 2 C   vs. 4% in   Fig. 2 A  ). In contrast, 
the proportion of these cells in tumor-bearing S100A9KO 
mice was the same as in tumor-free S100A9KO mice and 
signifi  cantly (P   <   0.05) lower than in tumor-bearing wild-
type mice (  Fig. 2 C  ). Thus, MDSCs do not accumulate in 
tumors in the absence of S100A9. 
  To address the need for S100A9 for MDSC generation in 
a tumor-independent model, we injected mice with CFA to 
mimic the conditions of infection and infl  ammation, which 
are known to stimulate production of MDSCs. The level of 
MDSCs was monitored in peripheral blood by fl  ow cytometry. JEM VOL. 205, September 29, 2008 
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onstrated high-level expression of targeted cDNA in hema-
topoietic cells from spleens, lymph nodes, and thymus (  34  ), 
as well as in HPCs and stem cells in bone marrow (  35  ). To 
better trace the expression of the transgene transcript, GFP 
was linked to the S100A9 cDNA behind an IRES sequence 
to permit independent translation (  Fig. 4 A  ). FVB/N mice 
derived from the zygotes injected with this H2K-S100A9-
GFP transgenic construct were genotyped by slot blot hy-
bridization to a GFP probe and phenotyped by FACS analysis 
for GFP expression in peripheral blood cells. Nine founder 
mice stably integrated the transgene. Expression of GFP pro-
tein in peripheral blood cells was signifi  cant in one founder 
mouse (  Fig. 4 B  , left). Transgene-positive off  spring from this 
founder line exhibited a consistent level of GFP expres-
sion during breeding for several generations to wild-type 
mice. The level of GFP expression was stable during the life-
time of these mice for at least 32 wk (the period of observa-
tion). The level of S100A9 protein in spleens obtained from 
allogeneic T cells than did cells diff  erentiated from control 
ES cells (  Fig. 3 D  ). 
    S100A9-  ,   A8-  , or   8/9  -transfected progeny did not ex-
press CD34 or Sca-1 markers. However, more than half of 
these cells expressed c-kit ( Fig. 4 E ), suggesting that S100A8/9 
might cause accumulation of myeloid progenitor cells.   This 
hypothesis was tested in a colony formation assay. Cells 
diff  erentiated from control ES cells did not form colonies, 
whereas a signifi  cant number of colonies were formed by cells 
diff  erentiated from S100A9 or S100A8/9 ES cells (  Figs. 3 F  ). 
Most of the colonies morphologically resembled granulocyte-
macrophage CFU-GMs (Fig. S8, available at http://www.jem
.org/cgi/content/full/jem.20080132/DC1). 
  To investigate the role of S100A9 in myeloid cell diff  er-
entiation in vivo, we generated transgenic mice (S100A9Tg) 
that overexpress S100A9 in hematopoietic cells under con-
trol of the H2K-promoter/enhancer and Moloney MuLV 
enhancer/poly(A) site (  34  ). This promoter previously dem-
    Figure 3.         Effect of S100A9 overexpression on DC differentiation from ES cells.   ES cells were transfected with empty vector (vector), S100A1, 
S100A8, S100A9, or a combination of S100A8 and 9 (S100A8/9). (A) Expression of   S100A8   and   A9   was evaluated in transfected ES cells using qRT-PCR. 
(B) Western blot assay for S100A9 and A8 in ES cells transfected with pcDNA-S100A9 and pcDNA-S100A8. Lane 1, empty vector; lane 2, S100A8; lane 3, 
S100A9; and lane 4, S100A8/9. (C) Phenotypes of cells generated from ES cells cultured for 35 d using the combination of cytokines described in Materials 
and methods. Expression of different surface molecules was evaluated by fl  ow cytometry. Mean and SD from four different experiments are shown. 
(D) Effector T cells were isolated from allogeneic BALB/c mice and 10  5   cells per well were mixed in triplicates of U-bottomed 96-well plates with different 
numbers of irradiated cells generated from ES cells. Vector, ES cells transfected with empty vector; S100A8/9, ES cells transfected with S100A8 and A9. 
Two different clones (#6 and #7) of ES cells are shown. HPC-DC, DCs generated from bone marrow progenitor cells by 5-d culture with GM-CSF and IL-4. 
T cell proliferation was measured by   3  [H]thymidine uptake and expressed as counts per minute (CPM). Three experiments were performed. Mean   ±   SD is 
shown. T cells alone showed   <  500 CPM count (not depicted). (E and F) Cells were generated from ES cells and either used for analysis of phenotype by 
fl  ow cytometry (E) or for colony formation in semisolid medium supporting the growth of myeloid colonies (StemCell Technologies). (F) Colony formation 
was evaluated in duplicates, and the number of colonies was calculated per 10  5   cells.   2240 S100A9 AND MYELOID CELL DIFFERENTIATION IN CANCER   | Cheng et al. 
cells were sorted from S100A9Tg mice (  Fig. 4 C  ). HPCs 
were cultured for 5 d with a cocktail of cytokines (Flt3, stem 
cell factor [SCF], IL-11, GM-CSF, and IL-3), followed by a 
7-d incubation with GM-CSF; LPS was present in the cul-
ture medium for the last 24 h. As shown in   Fig. 4 D  , the cells 
generated from wild-type HPCs were CD11c  +  IA  q+   DCs 
transgenic mice was substantially higher than in wild-type 
mice (  Fig. 4 B  , right). 
  To investigate the eff  ect of S100A9 on the diff  erentiation 
of myeloid cells, we isolated lineage-negative, c-kit  –  positive 
HPCs from bone marrow of control (wild-type) FVB/N mice 
and S100A9Tg mice. Lin       c-kit  +  GFP        and Lin       c-kit  +  GFP  +   
    Figure 4.         Effect of S100A9 overexpression on myeloid cell differentiation in transgenic mice.   (A) Vector used for generation of transgenic mice. 
(B, left) GFP  +   cells in peripheral blood of wild-type (WT) or transgenic mice (Tg) that express S100A9. (right) The level of S100A9 protein in spleens of wild-
type (WT) and S100A9 transgenic mice (Tg). (C) Bone marrow progenitor cells were enriched by lineage depletion kit (MACS), and then stained with a cocktail 
of lineage-specifi  c antibodies. Lin      c-kit +   GFP       or  GFP +   populations were sorted by fl  ow cytometry. (D) Sorted cells were cultured for 5 d with cocktail of 
cytokines as described in Materials and methods. After that time, media was replaced and 0.5   ×   10  6   cells were plated in 24-well plates and cultured with 
GM-CSF alone for additional 7 d. LPS was added for the last 24 h of culture. The phenotype of cells was evaluated using multicolor fl  ow cytometry. WT, 
wild-type FVB/N mice; GFP        and  GFP +  , S100A9 Tg mice. Three experiments were performed. (E) Sorted cells were used as stimulators of allogeneic (BALB/c) 
T cells. Cell proliferation was measured in triplicate 4-d cultures by   3  [H]thymidine uptake. Mean   ±   SD from two experiments are shown. T cells alone 
showed  count   < 500  CPM.   JEM VOL. 205, September 29, 2008 
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from naive FVB/N mice were stimulated with allogeneic 
DCs from BALB/c mice in the presence of IMCs. IMCs 
from S100A9Tg, but not wild-type mice, signifi  cantly sup-
pressed T cell proliferation at 1:2 and 1:4 ratios (  Fig. 5 F  ). 
  To assess possible eff  ects of S100A9 overexpression on 
tumor growth, wild-type and S100A9Tg mice were injected 
s.c. with 5   ×   10  5   AVN tumor cells. AVN cells were estab-
lished from a spontaneous, relatively immunogenic, slow-
growing tumor arising in FVB/N MMTV-Neu Tg mice 
(  36  ). Injection of tumor cells into S100A9Tg mice resulted in 
rapid tumor growth (  Fig. 5 G  ). Tumors were clearly detect-
able in all S100A9Tg mice by week 2 and were   >  200 mm  2   in 
size 1 wk later (mean size 286.5   ±   153.9 mm  2  ). In contrast, 
only a few tumors were visible by week 2 in wild-type mice. 
By day 25, the mean tumor size of wild-type mice was only 
84.6   ±   71.9 mm  2   (P = 0.001). 
  STAT3 regulates expression of S100A9 
  Previous studies have shown that the eff  ect of tumors on 
DCs and MDSCs is mediated via hyperactivation of the 
Jak2  –  STAT3 pathway, which is triggered by most of the 
tumor-derived factors implicated in abnormal myeloid cell 
diff  erentiation in cancer (  27, 30  ). The promoter regions of 
  S100A8   and   S100A9   contain several potential STAT3 bind-
ing sites (TTCCC G/A G/T AA). In chromatin immuno-
precipitation assays of 32D myeloid cells, STAT3 interacted 
with the promoter regions of both   S100A8   and   S100A9   
(  Fig. 6 A  ).   Thus, it is possible that STAT3 regulates the tran-
scription of   S100A8   and   S100A9  . 
  In support of this hypothesis, ES cells cultured in the pres-
ence of leukemia inhibitory factor (LIF) displayed functionally 
active phospho-STAT3 and high   S100A9   mRNA expression, 
whereas LIF withdrawal substantially reduced amounts of 
both pY  705  STAT3 and   S100A9   mRNA within 48 h (  Fig. 6, 
B and C  ). Expression of the constitutively active STAT3 mu-
tant STAT3C in ES cells maintained a high level of   S100A9   
expression after LIF withdrawal (  Fig. 6, B and C  ). 
  To examine the role of STAT3 in the regulation of 
  S100A9   expression in vivo  ,   we used Mx1-Cre/STAT3  loxP   
bitransgenic mice, which have an inducible deletion of the 
STAT3 gene (  31  ). In these mice, ablation of STAT3 in he-
matopoietic cells is achieved after injection of poly(I:C). 
STAT3  loxP/loxP   mice (without Mx1-Cre) were used as controls. 
Splenocytes were collected 10 d after injection of poly(I:C). 
Poly(I:C) treatment substantially reduced amounts of STAT3 
and S100A8/A9 in both Gr-1  +   and Gr-1        cells of Mx1-Cre/
Stat3  loxP   mice, but not of control mice (  Fig. 6 D  ). 
  Finally, we depleted STAT3 from 32D cells by RNA in-
terference. 32D cells were transfected with either control 
siRNA or STAT3 siRNA, and down-regulation of STAT3 by 
STAT3 siRNA was confi  rmed by Western blotting (  Fig. 6 F  ). 
STAT3 depletion resulted in the down-regulation of   S100A8   
and   S100A9   gene expression (  Fig. 6 E  ), as well as the levels 
of both proteins (  Fig. 6 F  ). Collectively, these data demon-
strate that STAT3 up-regulates the expression of S100A8 and 
S100A9 both in vitro and in vivo. 
(20%), F4/80  +  Gr-1        macrophages (30%), and Gr-1  +  CD11b  +   
immature myeloid cells (IMCs; 35%). No statistically signifi  -
cant diff  erences were found between the percentages of cell 
types generated from wild-type HPCs and GFP        HPCs from 
S100A9Tg mice. GFP  +   HPCs from S100A9Tg mice pro-
duced few DCs and macrophages, whereas   >  50% of the total 
cell population consisted of Gr-1  +  CD11b  +   IMCs (  Fig. 4 D  ). 
In contrast to cells generated from wild-type and GFP        trans-
genic HPCs, cells generated from GFP  +   transgenic HPCs 
failed to stimulate allogeneic T cells (  Fig. 4 E  ), confi  rming the 
very low presence of DCs. 
  The total number of GFP       Gr-1  +  CD11b  +   IMCs in 
S100A9Tg mice was the same as in wild-type mice. In con-
trast, the number of GFP  +   IMCs was fi  vefold higher than 
in wild-type mice. Although the total number of GFP  +   
IMC cells decreased in older mice, the diff  erence between 
S100A9Tg and wild-type mice was maintained (  Fig. 5 A  ).   
The proportions of DCs and macrophages were evaluated 
in spleens of 3-wk-old wild-type and S100A9Tg mice. In 
S100A9Tg mice, GFP  +   and GFP        populations were analyzed 
separately. No diff  erences were found in the proportions of 
DCs and macrophages between splenocytes from wild-type 
mice and GFP        splenocytes from S100A9Tg mice. In the 
population of GFP  +   splenocytes, the percentages of DCs and 
macrophages were signifi  cantly lower than in GFP        spleno-
cytes (  Fig. 5 B  ). 
  Next, we evaluated the level of myeloid precursors in 
wild-type and S100A9Tg mice. Percentages of c-kit  +   cells in 
bone marrow were sixfold higher in GFP  +   populations of 
S100A9Tg mice than in either GFP        populations or wild-
type mice (  Fig. 5 C  ). Diff  erences in c-kit expression in 
spleens were less dramatic but statistically signifi  cant (P   <   
0.05; unpublished data). The ability of bone marrow cells 
and splenocytes from S100A9Tg mice to form myeloid colo-
nies was signifi  cantly (P   <   0.05) greater than that of cells 
from wild-type mice (  Fig. 5 D   and Fig. S9, available at 
http://www.jem.org/cgi/content/full/jem.20080132/DC1). 
Collectively, these data indicate that overexpression of S100A9 
in hematopoietic cells results in accumulation of myeloid 
progenitors and IMC at the expense of DC and macro-
phage diff  erentiation. 
  To evaluate the possible immunosuppressive activity of 
IMCs generated in S100A9Tg mice, Gr-1  +  CD11b  +   cells 
were sorted from wild-type and transgenic tumor-free mice. 
Two experimental systems were used: peptide-specifi  c CD8  +   
T cell response and allogenic mixed leukocyte reaction. In 
the fi  rst experimental system, peptide-specifi  c CD8  +   T cells 
were generated by immunizing naive FVB/N mice with DCs 
loaded with MHC class I (H2-D  q  )  –  restricted rat HER-2/
  neu    –  derived peptide PDSLRDLSVF. Splenocytes were iso-
lated and stimulated with control or specifi  c peptide in the 
presence of IMCs. The number of IFN-      –  producing cells 
was evaluated by ELISPOT assay. IMCs from S100A9Tg 
mice signifi  cantly reduced the number of antigen-specifi  c 
CD8  +   T cells, whereas IMCs from wild-type mice did not 
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independent assays were performed. First, splenocytes (10  6  /ml) 
from control and S100A9Tg mice were cultured for 48 h, 
and extracellular levels of S100A8 and S100A9 proteins were 
measured by ELISA. The concentrations of the proteins were 
similar in both groups (    150 ng/ml). 
  S100A9 regulates myeloid cell differentiation via reactive 
oxygen species (ROS) 
  It is possible that overexpression of S100A9 in myeloid cells 
results in increased secretion of the protein, which in turn in-
hibits HPC diff  erentiation. To investigate this possibility, three 
    Figure 5.         Phenotype and functional activity of myeloid cells in S100A9 transgenic mice.   (A) S100A9Tg mice and their wild-type littermates were 
killed at indicated times after birth. The number of Gr-1  + CD11b +   cells in spleens of wild-type (control) and transgenic mice were evaluated. GFP        and 
GFP  +   splenocytes were counted separately. Each group included three mice. Mean   ±   SD is shown. (B) The proportion CD11c  +   DCs and F4/80  +   macrophages 
in spleens of 3-wk-old wild-type and transgenic mice. (C) The proportion of indicated populations of cells in bone marrow of wild-type and S100A9Tg 
mice. In transgenic mice, the proportion of cells was calculated separately for GFP  +   and  GFP       cells. Each group included three mice. Mean   ±   SD. * repre-
sents statistically signifi  cant differences between GFP  +   and  GFP       cells (P   <   0.05). (D) Colony formation assay of splenocytes and bone marrow cells iso-
lated from wild-type or S100A9Tg mice. Total myeloid colonies were calculated per 2   ×   10  5   cells in spleen and per 2   ×   10  4   cells in bone marrow. 
* represents statistically signifi  cant differences between WT and Tg mice (P   <   0.05). (E) Gr-1  + CD11b +   IMC were sorted from spleens of wild-type (WT) or 
S100A9Tg mice (Tg) and added at a 1:3 or 1:6 ratio to splenocytes from FVB/N mice immunized with specifi  c MHC class I  –  restricted PDSLRDLSVF peptide. 
Cells were stimulated with control (RAHYNIVTF) or specifi  c peptides, and the number of IFN-      –  producing cells was evaluated in quadruplicates in ELISPOT 
assay. The numbers of spots in cells stimulated with control peptide were subtracted from values in cells stimulated with specifi  c peptide. Mean   ±   SD 
from three experiments are shown. * represents statistically signifi  cant differences from splenocytes cultured without IMC (P   <   0.05). (F) Gr-1  + CD11b +  
IMCs were sorted from WT or S100A9Tg mice (Tg). In transgenic mice, these cells were separated into GFP  +   and  GFP       cells. T cells were isolated from na-
ive FVB/N mice and DCs were generated from bone marrow of naive BALB/c mice. DCs were mixed with T cells at 1:50 ratio and IMC were added at the 
indicated ratio. Cells were cultured in triplicates in round-bottomed 96-well plates for 4 d.   3  [H]thymidine uptake was measured. Mean   ±   SD from three 
experiments are shown. * represents statistically signifi  cant differences from splenocytes cultured without IMC (P   <   0.05). (G) AVN cells (5   ×   10  5 )  were 
injected s.c. into wild-type or S100A9Tg mice and tumor size was monitored. Each group included six mice.     JEM VOL. 205, September 29, 2008 
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Gr-1  +  GFP  +   cells from S100A9Tg mice than in Gr-1  +  GFP        
cells from wild-type and S100A9T mice (  Fig. 7 A  ). 
  We determined whether tumor burden aff  ected  ROS 
levels in MDSCs in S100A9KO mice. EL-4 tumors were es-
tablished in wild-type and S100A9KO mice, and ROS levels 
were evaluated in Gr-1  +  CD11b  +   MDSCs in spleens at a time 
when all mice had similar tumor sizes (12 d after tumor inoc-
ulation). Consistent with previous reports, MDSCs from 
wild-type, tumor-bearing mice produced substantially more 
ROS than did Gr-1  +  CD11b  +   IMCs from naive mice and 
(  Fig. 7 B  ).   ROS levels in IMCs from naive S100A9KO mice 
were only slightly lower than in IMCs from wild-type mice. 
However, ROS levels in MDSCs from tumor-bearing 
S100A9KO mice were substantially lower than in tumor-
bearing wild-type mice and were equivalent to ROS levels in 
naive wild-type mice (  Fig. 7 B  ). 
  We asked whether ROS aff  ected the diff  erentiation of 
MDSCs from tumor-bearing mice. EL-4 tumors were estab-
lished in wild-type and gp91      /      mice, which lack a critical 
component of the NADPH complex and produce very little 
ROS. MDSCs (90  –  95% pure) were isolated from spleens 
3 wk after tumor inoculation and cultured in the presence of 
GM-CSF and TCM for 7 d. MDSCs from tumor-bearing 
wild-type and gp91      /      mice expressed S100A9 (  Fig. 7 C  , in-
set). However, the lack of ROS in gp91      /      mice dramati-
cally enhanced MDSC diff  erentiation. Despite the presence 
of S100A9,   <  5% of gp91      /      cells retained an immature phe-
notype (Gr-1  +  CD11b  +  ) after 7 d in culture, compared with 
  Second, Lin       c-kit  +   myeloid progenitors derived from the 
bone marrow of naive FVB/N mice were placed in the bot-
tom chambers of 24-well Transwell plates. Splenocytes (1.5   ×   
10  6   cells per ml) from wild-type or S100A9Tg mice were 
placed in the top chambers (which are separated from the 
bottom chambers by a semipermeable membrane) and were 
cultured with a cocktail of cytokines supporting myeloid dif-
ferentiation. Splenocytes in the top chambers were replaced 
every 3 d. The progenitor cells diff  erentiated into mature 
myeloid cells regardless of whether the splenocytes in the top 
chambers overexpressed S100A9 or not (unpublished data). 
  Third, Lin       c-kit  +   progenitors were cultured in the pres-
ence of diff   erent concentrations of recombinant S100A8, 
S100A9, or S100A8/A9 heterodimer. None of these proteins 
at concentrations of 1 or 5   μ  g/ml signifi  cantly reduced the 
proportion of mature myeloid cells generated from myeloid 
progenitors. Collectively, the results suggest that overexpres-
sion of S100A9 inhibits myeloid diff  erentiation primarily via 
intracellular mechanisms. 
  We and others have previously shown that one of the 
main characteristics of MDSCs from tumor-bearing mice is 
high production of ROS (  28, 29, 37  ). Recent studies have 
implicated S100A9 protein in the regulation of ROS genera-
tion by NAPDH oxidase (  23, 38  –  41  ). We hypothesized that 
tumor-induced up-regulation of S100A9 in progenitors 
might inhibit myeloid diff  erentiation by increasing production 
of ROS. Consistent with this hypothesis, amounts of ROS in 
the spleen and bone marrow were four- to fi  vefold greater in 
    Figure 6.         Regulation of   S100A9   expression by STAT3 (A) ChIP assay.   Nuclear extracts from 32D cells were sonicated and ChIP with either anti-
STAT3 antibody (STAT3) or control rabbit IgG (IgG) was performed. PCR was performed with primers specifi  c for promoter regions of the   S100A9   (A9), 
  S100A8   (A8), or     -actin (C) genes. Input, PCR reaction performed with DNA isolated from nuclear extract without immunoprecipitation. (B and C) R1 ES 
cells were transfected with either control plasmid (R1-C) or Stat3C plasmid (R1-Stat3C) (  56  ) and cultured with complete medium containing LIF. (B) The 
level of Stat3 protein was determined by Western blotting prior (0 h) and 48 h (48 h) after LIF withdrawal from ES cells. (C) The expression of   S100A9   was 
measured by Southern blotting of RT-PCR products. (D) Deletion of STAT3 was achieved in STAT3  loxP/loxP   x Mx-Cre transgenic mice by two successive i.p. 
injections of 100   μ  g poly(I:C) 7 d apart. Undeleted STAT3  loxP/loxP   mice were used as a control. Gr-1  +   and  Gr-1       cells were isolated from spleens of control 
(STAT3 +) and STAT3 defi  cient mice (STAT3 -), and the levels of STAT3, S100A8, and S100A9 proteins were evaluated by Western blotting. Two experi-
ments with the same results were performed. (E and F) 32D cells were transfected with STAT3 siRNA. As a control, nontargeting siRNA pool was used 
(siGenome). (E) Expression of   S100A8  and  A9   mRNA was measured in quadruplicates by qPCR. Mean   ±   SD are shown. * represents statistically signifi  cant 
difference from control (P   <   0.05). (F) The level of indicated proteins was evaluated in Western blotting. Two experiments with the same results 
were  performed.   2244 S100A9 AND MYELOID CELL DIFFERENTIATION IN CANCER   | Cheng et al. 
    DISCUSSION   
  This study demonstrates a novel role for the Ca  2+   binding 
myeloid-related proteins S100A8 and S100A9 in myeloid cell 
diff  erentiation. It suggests that up-regulation of these proteins 
in HPCs is primarily responsible for defective myeloid cell 
diff  erentiation in cancer. S100A8 and S100A9 were previ-
ously implicated in traffi   cking of granulocytes and monocytes, 
especially during infl  ammation and metabolism of arachi-
donic acid (  23  ). Here, we show that up-regulation of these 
proteins results in inhibition of DC diff  erentiation and accu-
mulation of MDSCs. The STAT3 transcription factor up-
regulates the expression of   S100A8   and   S100A9  , which is 
consistent with the previous observation that diff  erent tu-
mor-derived factors mediate their immunosuppressive eff  ects 
via hyperactivation of Jak2  –  STAT3 signaling in myeloid cells 
(  27  ). Two of the cytokines (IL-10 and M-CSF) that were 
directly implicated in tumor-induced abnormalities of DCs 
(  42, 43  ) were previously found to up-regulate S100A9 (  44, 45  ). 
Consistent with these results, a direct connection between 
  >  30% of wild-type cells. Less than 10% of wild-type cells were 
F4/80  +  Gr-1        macrophages or CD11c  +   DCs. In sharp con-
trast, the majority of cells generated from gp91      /      MDSCs 
were macrophages and DCs (  Fig. 7 C  ). These fi  ndings sug-
gest that ROS mediate the inhibitory eff  ects of S100A9 on 
myeloid cell diff  erentiation. 
  To further explore this premise, F1 mice were generated by 
crossing S100A9Tg and gp91  phox   KO mice. As a control, we 
used the F1 cross of S100A9Tg mice with wild-type C57BL/6 
mice. Mice that contained GFP-positive cells and exhibited sub-
optimal ROS production in response to PMA stimulation were 
selected for experiments. Lin       c-kit  +   progenitor cells were sorted 
and cultured with a cocktail of cytokines to generate myeloid 
cells. Progenitor cells from gp91  phox  KO x S100A9Tg F1 mice 
produced signifi  cantly more CD11c  +   DCs and signifi  cantly less 
Gr-1  +  CD11b  +   cells than did progenitors from C57BL/6 x 
S100A9Tg mice (  Fig. 7 D  ). Collectively, these diverse data 
suggest that S100A9 may suppress myeloid cell diff  erentiation 
via persistent up-regulation of ROS in progenitor cells. 
    Figure 7.         S100A9 affects myeloid cell differentiation via up-regulation of ROS.   (A) ROS levels in S100A9Tg mice. Splenocytes and bone marrow 
cells were collected from 3-wk-old wild-type and S100A9Tg FVB/N mice. Cells were stimulated with PMA, labeled with APC-conjugated  anti – Gr-1  anti-
body, and loaded with the oxidation-sensitive dye hydroethidine. The level of ROS production was evaluated in GFP  +   or  GFP     Gr-1 +   cells. (left) fl  uores-
cence histograms from one typical experiment. (right) Graphs representing mean fl  uorescence intensity (MFI) in all performed experiments. Red, Gr-1  +  
cells from wild-type mice; green, GFP        Gr-1 +   cells from S100A9 Tg mice; blue, GFP  + Gr-1 +   cells from S100A9 Tg mice. Three experiments with the same 
results were performed. (B) EL-4 tumors were established in wild-type and S100A9KO mice as described in   Fig. 3  . Splenocytes were collected 12 d after 
tumor inoculation. Cells were stimulated with PMA and labeled with APC-conjugated anti  –  Gr-1 antibody and PE-conjugated anti-CD11b antibody. ROS 
were measured in Gr-1  + CD11b +   cells using DCFDA. Two experiments with similar results were performed. (C) EL-4 tumors were established in wild-type 
C57BL/6 or gp91     /     mice. 3 wk later, when tumors reached 1.5 cm in diameter, MDSCs were isolated from spleens using magnetic beads and cultured for 
7 d in vitro, as described in   Fig. 3 B  . Proportions of different cell populations were evaluated. Cumulative results from three experiments are shown. (inset) 
The level of S100A9 protein in freshly isolated MDSCs. (D) Phenotypes of cells in F1 offspring from crosses between S100A9Tg and gp91  phox   KO mice or 
wild-type C57BL/6 mice. Lin      c-kit +   progenitor cells were sorted and cultured with cocktail of cytokines to generate myeloid cells. Proportions of different 
cell populations were evaluated by fl  ow cytometry. Mean   ±   SD of cumulative results of two experiments is shown.     JEM VOL. 205, September 29, 2008 
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  Third, overexpression of S100A9 in myeloid cells of trans-
genic mice inhibited diff  erentiation of macrophages and DCs 
and induced the accumulation of IMCs. Cells overexpressing 
S100A9 had a potent suppressive eff  ect on T cell activity similar 
to that seen in tumor-associated MDSCs. Moreover, S100A9Tg 
mice were more susceptible to challenge with immunogenic 
tumors than wild-type mice. It is important to point out that 
this eff  ect may not necessarily be caused entirely by accumula-
tion of MDSCs or loss of DCs. Although our preliminary ex-
periments indicate that T cells from S100A9Tg mice do not 
express S100A9 and exhibit normal function, we cannot yet 
exclude a possible contribution of lymphoid cells to immune 
suppression in this mouse model. 
  Use of the S100A9 expression vector containing the GFP 
reporter allowed us to isolate GFP-positive cells with S100A9 
overexpression and to compare them to GFP-negative cells 
from the same mouse as an internal control to rule out con-
tributions of systemic or microenvironment eff  ects. Our data 
strongly suggest that S100A9 exerts its eff  ect on myeloid 
cell diff  erentiation via intracellular mechanisms rather than 
through extracellular secretion of protein. GFP        myeloid 
cells in S100A9Tg mice displayed a normal phenotype de-
spite the fact that they were located in close proximity to GFP  +   
cells that were dramatically aff  ected. In addition, splenocytes 
from control and Tg mice secreted similar levels of S100A9, 
as well as S100A8. Finally, soluble factors from S100A9Tg 
splenocytes, as well as recombinant proteins, did not aff  ect 
the diff  erentiation of wild-type myeloid cells. 
  The molecular mechanism of S100A8/A9 eff  ects on 
myeloid cell diff  erentiation is currently not clear and requires 
further investigation. Several potential mechanisms could 
be explored. 
  These proteins may aff  ect DC diff  erentiation via their 
Ca  2+   binding activity or by inhibiting casein kinase I and II 
activity, which may be associated with myeloid cell matura-
tion and function. Up-regulation of S100A9 may sensitize 
myeloid cells to the eff  ects of tumor-derived factors. For in-
stance, we have shown that overexpression of S100A9 results 
in up-regulation of c-kit on the surface of myeloid cells. Tu-
mor-derived SCF, the c-kit ligand, has been implicated in 
the accumulation of MDSCs in cancer (  52  ). However, the 
fact that S100A8 overexpression induced up-regulation of 
c-kit, but did not aff  ect production of Gr-1  +  CD11b  +   cells 
argues against a c-kit  –  dependent mechanism. Recently, a novel 
role of S100A9 as an endogenous ligand for Toll-like recep-
tor 4 (TLR4) was revealed (  53  ). We have previously demon-
strated that MDSC expansion requires signaling through the 
downstream target TLR MyD88 (  16  ). It is possible that hy-
peractivation of TLR signaling may interfere with the nor-
mal process of myeloid cell diff  erentiation, and S100A9 may 
be a major mediator of this eff  ect. 
  Another possible mechanism by which S100A8/A9 might 
inhibit myeloid cell diff  erentiation is linked to the ability of 
these proteins to facilitate ROS production by myeloid cells. 
S100A8/A9 is actively involved in the regulation of ROS 
generation by NAPDH oxidase (  23  ). Studies demonstrated 
STAT3 activity and S100A9 expression in breast cancer cells 
was recently reported (  46  ). 
  Several lines of evidence presented here support the con-
clusion that up-regulation of S100A9 causes inhibition of DC 
and macrophage diff  erentiation and accumulation of MDSCs. 
  First, S100A9 was crucial for the in vivo increase in the 
number of MDSCs in response to inoculation of mice with 
tumor cells or CFA. S100A9 was also critical for the inhibi-
tory eff  ects of tumor-derived factors on myeloid cell diff  er-
entiation in vitro  .   Our data showing normal myeloid cell 
diff  erentiation in naive S100A9KO mice are consistent with 
previous studies in which abnormalities in myeloid cells of 
S100A9KO mice were not detected (  32, 47  ). Apparently, 
under physiological conditions, S100A9 is not essential for 
myeloid cell diff  erentiation. However, in the pathological re-
sponse to challenge with tumor-derived factors or infection, 
S100A9 is required for both hyperproduction of MDSCs and 
blockade of DC diff  erentiation. 
  Second, overexpression of S100A9 in ES cells dramati-
cally compromised their ability to diff  erentiate into mature 
myeloid cells, particularly DCs and macrophages. The model 
of DC generation from ES cells has now been validated in 
several studies (  33, 48, 49  ), and it was chosen for our studies 
because precursors of granulocytes and monocytes normally 
express high levels of S100A9 (  23  ). Therefore, we hypothe-
sized that if S100A9 is important for myeloid diff  erentiation, 
it would most likely aff  ect the diff  erentiation of early pro-
genitor cells. Our data, indeed, demonstrate that S100A9 
overexpression blocks normal DC diff  erentiation. This is con-
sistent with the observation that mature DCs have very low 
or undetectable levels of this protein. Our results concur with 
those of Hashimoto et al., who performed serial analysis of 
gene expression in human DCs and found that, in contrast to 
monocytes, DCs did not express transcripts for S100A8 or 
S100A9 (  50  ). Apparently, to progress toward macrophage and 
DC diff  erentiation, myeloid cells must down-regulate S100A9 
expression. If such down-regulation is prevented, DC and 
macrophage diff  erentiation is halted. Instead, ES cells over-
expressing S100A8/A9 produced Gr-1  +   cells and myeloid 
progenitors able to form myeloid colonies, which is reminis-
cent of the phenomenon observed in tumor-bearing mice 
(  1  ). Because S100A8 and S100A9 form heterodimers, our 
initial hypothesis was that overexpression of both proteins 
would have a stronger eff  ect on DC diff  erentiation than 
would S100A9 alone. However, although double-transfected 
ES cells formed myeloid colonies more readily than did S100A9 
single transfectants, they aff  ected myeloid cell diff  erentiation 
equally. This may suggest that up-regulation of S100A9 ho-
modimers is suffi   cient to block DC diff  erentiation. In line 
with these fi  ndings was the observation that the eff  ect of S100A8 
overexpression on DC diff  erentiation was less pronounced 
than that of S100A9. In addition, S100A8 failed to induce the 
accumulation of Gr-1  +  CD11b  +   cells. Although diff  erent func-
tions of S100A9 and S100A8 have been described in several 
experimental systems (  51  ), more studies are needed to clarify 
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fer to remove red blood cells. Bone marrow cells were harvested from the 
femurs and tibias of mice and enriched for HPCs by depletion of lineage-
specifi  c cells, as previously described (  55  ). In brief, bone marrow cells were 
incubated with a mixture of antibodies (TIB-207, TIB-210, TIB-120, anti-
TER-119, anti-Gr-1, and anti-B220) for 30 min on ice, washed, and treated 
with complement for 1 h at 37  °  C. Dead cells were then removed by centrif-
ugation over a Lympholyte M gradient. The resulting fraction contained 
  <  20% of lineage-positive cells as detected by fl  ow cytometry. 500,000 en-
riched HPCs were placed into each well of 24-well plates in 2-ml of RPMI 
supplemented with 10% FBS, 20 ng/ml GM-CSF, and 10 ng/ml IL-4. This 
complete medium was replaced every 3 d, and cells were collected for fur-
ther analysis at indicated time points. To assess the eff  ects of tumor-derived 
factors on DC diff  erentiation, HPCs were fed with complete medium sup-
plemented with 25% medium conditioned for 48 h by subconfl  uent cultures 
of NIH 3T3 fi  broblasts as a control, or the C3, CT26, or EL4 tumor cell 
lines. For DC activation, 5 ng/ml TNF-     was added to RPMI complete 
medium for 48 h or 1   μ  g/ml LPS for 24 h before cell analysis. 
  CTL assay.     Splenocytes from EL4 tumor-bearing mice were cultured for 
7 d with irradiated EL4 cells, in 10% FBS RPMI, supplemented with 20 ng/ml 
IL-15 and 20 ng/ml IL-21. On day 7, cytotoxicity was performed in a stan-
dard 6-h   51  Cr-release CTL assay. The target cells were EL-4 incubated in 
duplicates at a serials eff  ector/target ratio. 
  Real-time qPCR.     Total RNA was extracted from cells with Trizol (Invit-
rogen). Traces of DNA were removed by treatment with DNase I. The 
cDNA was synthesized from 1   μ  g of total RNA using random hexamers and 
Superscript II reverse transcription (Invitrogen) according to the manufac-
turer  ’  s protocol. PCR was performed with 2.5   μ  l cDNA, TaqMan Universal 
PCR Master Mix (Applied Biosystems), and target gene assay mix contain-
ing sequence-specifi  c primers for S100A8 or S100A9 and 6-carboxyfl  uores-
cein (6-FAM) dye-labeled TaqMan minor groove binder (MGB) probe 
(Applied Biosystems). Amplifi  cation with 18S endogenous control assay mix 
was used for controls. Data quantitation was performed using the relative 
standard curve method. Expression levels of the genes were normalized by 
18S rRNA. 
  RT-PCR and Southern blots.     Total RNA was extracted from cells with 
Trizol. Traces of DNA were removed by treatment with DNase I. The 
cDNA was synthesized from 1   μ  g of total RNA using random hexamers and 
Superscript II reverse transcription according to the manufacturer  ’  s protocol. 
Samples were subjected to initial denaturation at 94 °  C for 3 min and 24 cycles 
(for  S100A8   and  S100A9  ) or 28 cycles (for  hprt  ) of PCR (94 °  C for 30 s, 54 °  C 
for 30 s, and 72  °  C for 45 s) with fi  nal extension for 7 min at 72  °  C. The num-
ber of cycles was selected after preliminary experiments to avoid saturation of 
the PCR products. PCR primer pairs used in this study include the follow-
ing:   S100A8   forward for HPC and DC cultures: 5    -ACAATGCCGTCT-
GAACTGG; reverse, 5    -CTCTGCTACTCCTTGTGGCTGTCT-3    , or 
  S100A8   forward for ES transfectants, 5    -GGAAATCACCATGCCCTC-
TACAA-3    ; reverse, 5    -ATGCCACACCCACTTTTATCACC-3    .   S100A9   
forward for HPC and DC cultures, 5    -GGAGCGCAGCATAACCAC-3    ; 
reverse, 5    -GCCATTGAGTAAGCCATTCC-3    , or   S100A9   forward for 
ES transfectants, 5    -CATCGACACCTTCAATCAATACTC-3    ; reverse, 
5    -GCCATCAGCATCATACACTCCTC-3    .   hprt  : forward, 5    -GATT-
CAACTTGCGCTCATCTTAGGC-3    ; reverse, 5    -GTTGGATACAG-
GCCAGACTTTGTTG-3    . The PCR products were separated on 1% 
agarose gels. The sizes of PCR products were: 279 bp for   S100A8   in HPC 
and DCs and 174 bp for ES transfectants; 378 bp for   S100A9   in HPC and 
DC cultures and 206 bp for ES transfectants; and 164 bp for   hprt.   PCR prod-
ucts were transferred in an alkaline buff  er (0.4 N NaOH, 1 M NaCl) onto 
Hybond N  +   nylon transfer membranes (GE Healthcare), and probed with 
  32  P-labeled oligonucleotide probes:   S100A8  , 5    -GGAGTTCCTTGCGAT-
GGTGATA-3    ;   S100A9  , 5    -ACATCATGGAGGACCTGGACACA-3    ; 
  hprt  , 5    -GTTGTTGGATATGCCTTGAC-3    . 
  Western blot analyses were performed as previously described (  27  ). 
that S100A8 and S100A9 directly bind to p67  phox   and p47  phox  , 
critical components of the NADPH complex (  38, 39  ). This 
binding potentiates NADPH oxidase activation in neutro-
phils. Furthermore, S100A9 inhibits the expression of a sub-
stantial number of genes in myeloid cells, including gp91  phox   
(  50  ), suggesting that diff  erences in ROS production in the 
absence of S100A9 may refl  ect a general role of this protein 
during myeloid diff  erentiation. ROS, in turn, are the major 
factors inhibiting diff   erentiation of DCs in tumor-bearing 
mice (  29  ). Our data ROS play an important role in S100A9-
mediated eff  ects on myeloid cell diff  erentiation. 
  In recent years, it has become increasingly evident that 
infl  ammation plays a critical role in tumor progression (  54  ). 
This study not only demonstrates a novel molecular mecha-
nism responsible for the suppression of immune responses in 
cancer via accumulation of MDSCs but also provides a po-
tential direct molecular link between immune suppression, 
MDSCs, and proinfl  ammatory factors. Together with present 
and previous observations that lack of S100A9 or STAT3 
function promotes tumor rejection via immunological mech-
anisms (  31  ), these cumulative fi  ndings reveal a pathway that 
negatively regulates the immune response in cancer. 
    MATERIALS AND METHODS   
  Reagents.     The following antibody-producing hybridomas were purchased 
from the American Type Culture Collection (ATCC) and used as supernatants: 
anti-CD4 (L3T4, TIB-207), anti-CD8 (Lyt-2.2, TIB-210), and anti-MHC II 
(TIB-120). Anti-IA  b  , IAd/IEd, Gr-1, CD4, CD8, CD11b, CD86 (B7-2), 
CD45, CD11c, CD34, Sca-1, c-Kit, isotype control antibodies, and mouse cell 
lineage depletion kit were obtained from BD Biosciences. Anti-CD3 and anti  –
  Ter-119 antibodies were obtained from BioLegend, anti-F4/80 antibody from 
Serotec, streptavidin microbeads and mouse lineage cell depletion kit from 
Miltenyi Biotec, anti  –  mouse S100A8, and anti-S100A9 from Santa Cruz Bio-
technology. For immunohistochemical staining, anti-S100A9, anti  –  goat, anti  –
  rat conjugated with biotin antibodies, and Vectastain ABC kit were purchased 
from Vector Laboratories. Myeloid Long-Term Culture Medium for Primitive 
Mouse Hematopoietic Cells (MyeloCult media) and hydrocortisone were pur-
chased from StemCell Technologies. Low-Tox rabbit complement and Lym-
pholyte M were obtained from Cedarlane Laboratories. Recombinant murine 
GM-CSF, IL-4, TNF-    , IL-3, IL-11, Flt3L, and SCF were obtained from 
R  &  D Systems. LPS was obtained from Sigma-Aldrich. For depletion of CD8  +   
cells anti-CD8 Lyt 2.2 antibody (ATCC) were generated as ascitis (provided by 
E. Celis, H. Lee Moffi   tt Cancer Center, Tampa, FL). Recombinant S100A9 
and A8 proteins were previously described (  53  ). AVN mammary carcinoma 
cell line was provided by K. Knutson (Mayo Clinic, Rochester, MN). 
  Animals.     6  –  8-wk-old female BALB/c and C57BL/6 mice were pur-
chased from Harlan. FVB/N mice were purchased from Charles River 
Laboratories. The gp91  phox   KO and OT-1 mice were obtained from The 
Jackson Laboratory. 
  S100A9-defi   cient mice were previously described (  32  ) and housed in 
pathogen-free units of the Division of Comparative Medicine vivarium at 
H. Lee Moffi   tt Cancer Center, University of South Florida. These mice were 
backcrossed for six generations to C57BL/6 mice. Control groups included mice 
with wild-type genotype (S100A9  +/+  ) from the same generation of backcross. 
  All animal experiments were approved by the Institutional Animal Care 
and Use Committee and performed in accordance with U.S. Public Health 
Service policy and National Research Council guidelines. 
  Preparation of cells.     Spleens were collected from control or tumor-bear-
ing mice. Single-cell suspensions of splenocytes were treated with ACK buf-JEM VOL. 205, September 29, 2008 
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promoter at the NotI site of pH2K-i-LTR that had been previously modi-
fi  ed to convert a 5     EcoRI site to SalI (provided by P. Persons, St. Jude 
Children’s Hospital, Memphis, TN). After verifi  cation of construct orienta-
tion and sequence, the 5.15-kb H2K-S100A9-IRES-GFP transgene was 
isolated by SalI digestion and electroelution from 1% agarose gel, followed 
by ethanol precipitation. To generate H2K-S100A9 transgenic mice, the 
Moffi   tt Mouse Models Core facility microinjected the purifi  ed DNA at 
3 ng/  μ  l into pronuclei of 0.5 dpc fertilized zygotes from the FVB/N strain 
and implanted surviving embryos into the oviducts of pseudopregnant CD1 
foster recipients per standard procedures. Transgenic founders and their 
off  spring were genotyped by slot-blot hybridization of tail DNA to a radio-
labeled GFP probe. 
  Generation of myeloid cells from sorted HPCs in transgenic mice.   
  Bone marrow cells obtained from wild-type or S100A9Tg mice were de-
pleted of lineage-positive cells using mouse lineage cell depletion kit (Milte-
nyi Biotec), and stained with the following antibodies: pacifi  c blue  –  conjugated 
CD3; Percp-conjugated CD4, CD8, Ter-119, CD11b, Gr-1, and B220; and 
APC-conjugated c-kit. Lin       c-Kit  +   GFP  +   and Lin       c-Kit  +   GFP        stem cells 
were sorted using a FACSAria. To diff  erentiate myeloid progenitor cells, 
35,000 Lin       c-Kit  +   GFP  +   or Lin       c-Kit  +   GFP        cells were placed in each well 
of 24-well plates and cultured for 5 d in Myeloid Long-Term Culture Me-
dium for Primitive Mouse Hematopoietic Cells, supplemented with 20 ng/ml 
of IL-3, IL-11, SCF, Flt3L and GM-CSF. 500,000 cells were cultured in 
RPMI supplemented with 10% FBS and 20 ng/ml of GM-CSF for another 
7 d. 24 h before cell analysis, 1   μ  g/ml LPS was added to activate DCs. 
  Isolation of Gr-1  +   cells.     Gr-1  +   cell isolation was performed using Mini-
MACS microbeads according to the manufacturer  ’  s protocol (Miltenyi Bio-
tec). The purity of Gr-1  +   cells was consistently   >  95% in all samples. The 
depletion of Gr-1  +   cell was achieved by two rounds of isolation using mag-
netic beads. Negative fractions were collected and used as Gr-1        cells. They 
contained   <  5% Gr-1  +   cells. In some experiments, Gr-1  +  CD11b  +   cells were 
sorted using FACSAria cell sorter (BD Biosciences). 
  IFN-     ELISPOT assay.     MDSCs were isolated from spleens of wild-type 
and S100A9Tg mice using cell sorting on FACSAria cell sorter. The purity 
of cell populations was   >  99%. As responder cells, we used splenocytes from 
FVB/N mice immunized twice with s.c. injection of 5   ×   10  5   DCs loaded 
with MHC class I (H2-D  q  ) restricted rat HER-2/  neu    –  derived peptide PD-
SLRDLSVF. MDSCs were mixed with splenocytes at 1:3 and 1:6 ratios. 
The number of IFN-      –  producing cells in response to stimulation with the 
specifi  c (PDSLRDLSVF) or control (RAHYNIVTF) peptides (10   μ  g/ml) 
was evaluated in a 42-h ELISPOT assay performed as previously described 
(  57  ). The numbers of spots were counted in triplicates and calculated using 
an automatic ELISPOT counter (Cellular Technology, Ltd). 
  Allogeneic mixed leukocyte reaction.     T cells were isolated from naive 
FVB/N mice using a T cell enrichment column (R  &  D Systems), and 10  5   
cells were placed in each well of round-bottomed 96-well plates. DCs were 
generated from BALB/c mice using GM-CSF and IL-4. DCs were mixed 
with T cells at a 1:50 ratio. MDSCs isolated from wild-type and S100A9Tg 
mice were added to cultures at diff  erent MDSC/T cells ratios (from 1:2 to 
1:16). Cell proliferation was evaluated in triplicates after a 96-h incubation 
using   3  [H]thymidine incorporation. 
  Measurement of ROS.     ROS was measured by labeling cells either with the 
oxidation-sensitive dye DCFDA (  28  ) for experiments with S100A9 KO mice 
and ES cells or hydroethidine (  58  ) for experiments with S100A9 Tg mice. 
  Hematoxylin-eosin and immunohistochemical staining of tumor 
tissues.     EL4 tumor tissues were either fi  xed in paraformaldehyde or frozen 
with OCT. Hematoxylin-eosin staining was performed on paraffi   n embed-
ding tissues. 5-  μ  m-thick sections were stained with hematoxylin-eosin and 
examined under light microscopy. Immunohistochemical staining was 
  Chromatin immunoprecipitation assay (ChIP).     32D cells were cul-
tured in 10% FBS RPMI 1640 supplemented with IL3. Preparation of 
chromatin-DNA and ChIP assay were performed with kit (Millipore) 
per the manufacturer  ’  s instructions, using antibodies against STAT3 (Cell 
Signaling Technology), normal rabbit IgG (Santa Cruz Biotechnology), 
and protein A agarose/salmon sperm DNA (Millipore). Sonication was 
performed using a Branson Sonifi  er (model 450; VWR Scientifi  c). Af-
ter reversal of cross-linking, purifi  ed DNA was subjected to PCR with the 
following primers spanning the potential STAT3 binding site in the 
S100A9 promoter: forward 5    -ACTTCTGGAAATCAGTCTGGC-
GGT-3    ; reverse, 5    -T  GGGTTCTTTCCAGCTTCTGGCTA-3    . Primers 
for S100A8 promoter: forward, 5    -ACACCTCGTACAACTGGAACC-
ACA-3    ; reverse, 5    -TCAGCATC  A  TCCAAGAGAGCCCAA-3    . Primers 
for     -actin: forward, 5    -T  A  G  G  G  T  G  TAGACTCTTTGCAGCCA-3    ; 
reverse, 5    -A  G  C  G  T  C  T  G  GTTCCCAATACTGTGT-3    . 
  Experiments with ES cells.       S100A1  ,   S100A8  , and   S100A9   were ampli-
fi  ed from mRNA of HPC cells isolated from BALB/c bone marrow us-
ing RT-PCR. The pairs of primers were as follows: for   S100A1   forward, 
5    -GCTCGAGGCCACCATGGGCTCTGAG-3     containing XhoI site; 
reverse, 5    -AGAATTCGTGCTCAACTGGTCTCCCA-3    ; containing 
EcoRI site;   S100A8   forward, 5    -CTCGAGCCACCATGCCGTCTG  A-
ACTG-3    , containing XhoI site at the 5     end and modifi  ed Kozak sequence; 
reverse, 5    -CAGGAATTCAGCCCTAGGCCAGAAG-3    , containing EcoRI 
site at 5     end;   S100A9   forward, 5    -AGATATCAGATCTGCCACCATG-
GCCAACAAAGCA-3    , containing EcoRV and BglII sites at 5     end and 
modifi  ed Kozak sequence; reverse, 5    -AGTCTCGAGGCTGACCTCT-
TAATTA-3    , containing XhoI site at 5     end. For   S100A8,   the amplifi  ed 
311-bp fragment was digested using XhoI and EcoRI, and subsequently 
inserted into pcDNA3.1(-). For   S100A9,   the amplifi  ed 375-bp fragment 
was digested using EcoRV and XhoI, and inserted into pcDNA3.1(+). 
  S100A1   fragment was cloned into pcDNA3.1(-). The vectors were verifi  ed 
by sequencing. To create cell lines expressing both   S100A8   and   S100A9,   
the latter gene was recloned using EcoRV and XhoI into pcDNA3-Hygro. 
R1 ES cells were transfected with Lipofectamine (Invitrogen) mixed with 
empty pcDNA3.1 vector; pcDNA3.1 containing S100A1, S100A9, or both 
S100A8 and S100A9 (S100A8/9); or the STAT3c plasmid (R1-Stat3C, (  56  ) 
or its vector control RcCMV-Neo (R1-C). ES cells were grown in knock-
out DMEM containing 2 mM   l-  glutamine, 0.1 mM nonessential amino 
acids, 100   μ  M 2-mercaptoethenol, 15% ES cell certifi  ed FBS (Invitrogen), 
1,000 U/ml LIF (ESGRO; Chemicon International, Inc.), and 200   μ  g/ml 
G418 or both G418 and 100   μ  g/ml hygromycin. 
  DC diff  erentiation from S100A9-overexpressing ES cells.     Diff  erenti-
ation of DCs from ES cells was performed as previously described (  33  ). In 
brief, ES cells were grown on gelatinized plates in complete knockout 
DMEM, as described above. To induce formation of embryoid bodies, ES 
cells were transferred to bacterial-grade Petri dishes in medium without LIF 
and cultured for 14 d; they were fed every other day. On day 14, 1 EB was 
transferred to each well of a 24-well plate and incubated for 30 d in 2 ml/
well RPMI medium containing 15% FBS, 20 ng/ml GM-CSF, and 10 ng/ml 
IL-3. Half of the medium was changed every 3 d. 5 ng/ml TNF-     was added 
for the last 5 d before analysis. 
  Assessment of colony formation.     Colony formation by cells derived from 
in vitro diff  erentiation was measured using semisolid 1% methylcellulose me-
dium supplemented with recombinant cytokines supporting the optimal 
growth of myeloid colonies (MethoCult M3534; Stem Cell Technologies). 
Cells generated from ES cells on day 35 were collected and seeded at 25,000 
cells/well in 6-well plates. Colonies were scored on day 10. 
  S100A9 transgenic mice.     The 375-bp BglII  –  XhoI   S100A9   fragment 
from pcDNA-S100A9 was inserted into pMIGR1 upstream of an IRES-
GFP. A 1.65-kb BglII  –  SalI fragment containing S100A9-IRES-GFP was 
end-fi  lled and ligated to NotI linkers and cloned downstream of the H2K 2248 S100A9 AND MYELOID CELL DIFFERENTIATION IN CANCER   | Cheng et al. 
proves diff  erentiation of myeloid cells and immune response in cancer 
patients.       Cancer Res.       66  :  9299    –    9307  .    
       8  .   Fricke  ,   I.  ,   N.     Mirza  ,   J.     Dupont  ,   G.     Lockhart  ,   A.     Jackson  ,   J.-H.     Lee  , 
  J.A.     Sosman  , and   D.I.     Gabrilovich  .   2007  .   Treatment of cancer patients 
with VEGF-Trap overcomes defects in DC diff  erentiation but is insuf-
fi  cient to improve antigen-specifi  c immune responses.       Clin. Cancer Res.     
  13  :  4840    –    4848  .    
       9  .   Zea  ,   A.H.  ,   P.C.     Rodriguez  ,   M.B.     Atkins  ,   C.     Hernandez  ,   S.     Signoretti  , 
  J.     Zabaleta  ,   D.     McDermott  ,   D.     Quiceno  ,   A.     Youmans  ,   A.     O  ’  Neill  ,   et al  . 
  2005  .   Arginase-producing myeloid suppressor cells in renal cell carcinoma 
patients: a mechanism of tumor evasion.       Cancer Res.       65  :  3044    –    3048  .   
        10  .   Sinha  ,   P.  ,   V.K.     Clements  ,   A.M.     Fulton  , and   S.     Ostrand-Rosenberg  . 
  2007  .   Prostaglandin E2 promotes tumor progression by inducing my-
eloid-derived suppressor cells.       Cancer Res.       67  :  4507    –    4513  .    
        11  .   Huang  ,   B.  ,   P.Y.     Pan  ,   Q.     Li  ,   A.I.     Sato  ,   D.E.     Levy  ,   J.     Bromberg  ,   C.M.   
  Divino  , and   S.H.     Chen  .   2006  .   Gr-1+CD115+ immature myeloid sup-
pressor cells mediate the development of tumor-induced T regulatory cells 
and T-cell anergy in tumor-bearing host.       Cancer Res.       66  :  1123    –    1131  .    
        12  .   Nagaraj  ,   S.  ,   K.     Gupta  ,   V.     Pisarev  ,   L.     Kinarsky  ,   S.     Sherman  ,   L.     Kang  ,   D.   
  Herber  ,   J.     Schneck  , and   D.     Gabrilovich  .   2007  .   Altered recognition of 
antigen is a novel mechanism of CD8+ T cell tolerance in cancer  .     Nat. 
Med.       13  :  828    –    835  .    
        13  .   Kusmartsev  ,   S.  ,   S.     Nagaraj  , and   D.I.     Gabrilovich  .   2005  .   Tumor-associ-
ated CD8+ T cell tolerance induced by bone marrow-derived imma-
ture myeloid cells.       J. Immunol.       175  :  4583    –    4592  .   
        14  .   Antonia  ,   S.J.  ,   N.     Mirza  ,   I.     Fricke  ,   A.     Chiappori  ,   P.     Thompson  ,   N.   
  Williams  ,   G.     Bepler  ,   G.     Simon  ,   W.     Janssen  ,   J.H.     Lee  ,   et al  .   2006  . 
  Combination of p53 cancer vaccine with chemotherapy in patients with 
extensive stage small cell lung cancer.       Clin. Cancer Res.       12  :  878    –    887  .    
        15  .   Shojaei  ,   F.  ,   X.     Wu  ,   A.K.     Malik  ,   C.     Zhong  ,   M.E.     Baldwin  ,   S.     Schanz  , 
  G.     Fuh  ,   H.P.     Gerber  , and   N.     Ferrara  .   2007  .   Tumor refractoriness to 
anti-VEGF treatment is mediated by CD11b(+)Gr1(+) myeloid cells.   
    Nat. Biotechnol.       25  :  911    –    920  .    
        16  .   Delano  ,   M.J.  ,   P.O.     Scumpia  ,   J.S.     Weinstein  ,   D.     Coco  ,   S.     Nagaraj  ,   K.M.   
  Kelly-Scumpia  ,   K.A.     O  ’  Malley  ,   J.L.     Wynn  ,   S.     Antonenko  ,   S.Z.     Al-
Quran  ,   et al  .   2007  .   MyD88-dependent expansion of an immature GR-
1  +  CD11b  +   population induces T cell suppression and Th2 polarization 
in sepsis.       J. Exp. Med.       204  :  1463    –    1474  .    
        17  .   Gomez-Garcia  ,   L.  ,   L.M.     Lopez-Marin  ,   R.     Saavedra  ,   J.L.     Reyes  ,   M.   
  Rodriguez-Sosa  , and   L.I.     Terrazas  .   2005  .   Intact glycans from cestode 
antigens are involved in innate activation of myeloid suppressor cells.   
    Parasite Immunol.       27  :  395    –    405  .    
        18  .   Ezernitchi  ,   A.V.  ,   I.     Vaknin  ,   L.     Cohen-Daniel  ,   O.     Levy  ,   E.     Manaster  , 
  A.     Halabi  ,   E.     Pikarsky  ,   L.     Shapira  , and   M.     Baniyash  .   2006  .   TCR zeta 
down-regulation under chronic infl  ammation is mediated by myeloid 
suppressor cells diff  erentially distributed between various lymphatic 
organs.       J. Immunol.       177  :  4763    –    4772  .   
        19  .   MacDonald  ,   K.P.  ,   V.     Rowe  ,   A.D.     Clouston  ,   J.K.     Welply  ,   R.D.     Kuns  , 
  J.L.     Ferrara  ,   R.     Thomas  , and   G.R.     Hill  .   2005  .   Cytokine expanded my-
eloid precursors function as regulatory antigen-presenting cells and pro-
mote tolerance through IL-10-producing regulatory T cells.       J. Immunol.     
  174  :  1841    –    1850  .   
        20  .   Paraiso  ,   K.H.  ,   T.     Ghansah  ,   A.     Costello  ,   R.W.     Engelman  , and   W.G.   
  Kerr  .   2007  .   Induced SHIP defi  ciency expands myeloid regulatory cells 
and abrogates graft-versus-host disease.       J. Immunol.       178  :  2893    –    2900  .   
        21  .   Foell  ,   D.  , and   J.     Roth  .   2004  .   Proinfl  ammatory S100-proteins in arthritis 
and autoimmune disease.       Arthritis Rheum.       50  :  3762    –    3771  .    
        22  .   Leukert  ,   N.  ,   T.     Vogl  ,   K.     Struppat  ,   R.     Reichelt  ,   C.     Sorg  , and   J.     Roth  . 
  2006  .   Calcium-dependent tetramer formation of S100A8 and S100A9 
is essential for biological activity.       J. Mol. Biol.       359  :  961    –    972  .    
        23  .   Nacken  ,  W.  ,  J.    Roth  ,  C.    Sorg  , and  C.    Kerkhoff    .  2003  .  S100A9/S100A8: 
myeloid representatives of the S100 protein family as prominent players 
in innate immunity.       Microsc. Res. Tech.       60  :  569    –    580  .    
        24  .   Hiratsuka  ,   S.  ,   A.     Watanabe  ,   H.     Aburatani  , and   Y.     Maru  .   2006  .   Tumour-
mediated upregulation of chemoattractants and recruitment of myeloid 
cells predetermines lung metastasis.       Nat. Cell Biol.       8  :  1369    –    1375  .    
        25  .   Menetrier-Caux  ,   C.  ,   M.C.     Thomachot  ,   L.     Alberti  ,   G.     Montmain  , and 
  J.Y.     Blay  .   2001  .   IL-4 prevents the blockade of dendritic cell diff  erentia-
tion induced by tumor cells.       Cancer Res.       61  :  3096    –    3104  .   
performed on frozen tissue sections using goat anti  –  mouse S100A9 antibody 
(R  &  D Systems), followed by staining with anti  –  goat IgG conjugated with 
biotin and ABC kit (Vector Laboratories) and counterstained with hematox-
ylin or stained with rat anti  –  mouse Gr-1 antibody (BD Biosciences), fol-
lowed by staining with anti-rat IgG conjugated with biotin and ABC kit 
(Vector Laboratories) and counterstained with hematoxylin. 
  Down-regulation of Stat3 by siRNA in 32D cells.     32D cells (10  6  ) were 
mixed with 100 nM Stat3 siRNA (Dharmacon) in 100   μ  l 32D nucleofector 
solution, and transfection was performed using Nucleofector I (Amaxa). As 
a control, nontargeting siRNA pool was used (siGenome). The gene expres-
sion was evaluated 36 h later using qRT-PCR, and protein levels were mea-
sured after 72 h by Western blotting. 
  Statistics.     Statistical analysis was performed using parametric and nonpara-
metric methods on JMP software (SAS Institute). In all cases, P values were 
calculated using two-sided   t   test. 
  Online supplemental material.     Fig. S1 shows the expression of   S100A9   
and   A8   in myeloid cells in tumor-bearing mice. Fig. S2 demonstrates that 
tumor cell-conditioned medium inhibits diff  erentiation of DCs and induces 
accumulation of MDSCs in vitro. Fig. S3 shows that diff  erentiation of my-
eloid cells in S100A9-defi  cient naive mice is not impaired. Fig. S4 shows 
that C3 tumor is rejected by most of S100A9 KO mice. Fig. S5 provides the 
analysis of cytotoxicity by T cells from S100A9 KO mice. Fig. S6 shows the 
immunohistochemical evaluation of tumors from S100A9 KO mice. Fig. S7 
demonstrates the expression of   S100A9   and   A8   in transfected ES cells. 
Fig. S8 shows the phenotype of myeloid cell colonies in cells transfected with 
S100A9/A8. Fig. S9 shows the colony formation by spleen and bone mar-
row cells from S100A9Tg mice. The online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20080132/DC1. 
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